PETMED EXPRESS Earnings Report and Insider Activity Ahead of May Release

PETMED EXPRESS ($PETS) is set to publish its quarterly earnings data on Monday, May 12th, following market closure, according to Finnhub. Analysts project revenue of $55,080,000 and earnings of -$0.05 per share.

Insider Trading Activity at PETMED EXPRESS

In the last six months, PETMED EXPRESS insiders have engaged in stock transactions 21 times. Among these, 19 trades were purchases while 2 were sales.

Below is a summary of insider trading involving $PETS over the past six months:

• CAPITAL HOLDINGS INC. NINA conducted 8 purchases, acquiring 372,000 shares for an estimated $1,706,885, with no sales reported.
• LESLIE C.G. CAMPBELL made 11 purchases, securing 60,000 shares for an estimated $324,635, and reported no sales.
• SANDRA YVETTE CAMPOS (CEO & President) recorded no purchases but sold 60,463 shares for an estimated $200,090.

Hedge Fund Activity Involving PETMED EXPRESS

Recent data shows that 35 institutional investors have increased their holdings in PETMED EXPRESS, while 49 have reduced their investments in the past quarter.

Here are some notable transactions from recent quarters:

• D. E. SHAW & CO., INC. removed 149,495 shares (-46.5%) in Q4 2024, valued at approximately $720,565.
• HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC decreased their portfolio by 116,600 shares (-10.7%) in Q4 2024, totaling about $562,012.
• METAVASI CAPITAL LP increased their portfolio by 111,194 shares (+48.5%) in Q4 2024, worth around $535,955.
• ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 107,614 shares (+26.5%) in Q4 2024, valued at approximately $518,699.
• CHARLES SCHWAB INVESTMENT MANAGEMENT INC cut 99,186 shares (-90.8%) from their holdings in Q1 2025, equating to about $415,589.
• CUBIST SYSTEMATIC STRATEGIES, LLC completely exited their position by removing 95,309 shares (-100.0%) in Q4 2024, totaling roughly $459,389.
• SCHONFELD STRATEGIC ADVISORS LLC also exited by selling 90,500 shares (-100.0%) in Q4 2024, valued at approximately $436,210.

This article does not constitute financial advice. For further details, check Quiver Quantitative’s disclaimers. Note that inaccuracies may stem from ticker mapping errors and other anomalies.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.